What is Celula?
Celula is a specialized entity focused on the development and provision of integrated diagnostic solutions. The company's core competencies lie in advancing prenatal testing methodologies and enhancing cancer detection capabilities, with a particular emphasis on improving the accuracy of women's diagnostics. Celula is also dedicated to the early detection of ovarian cancer and offers research and development partnership opportunities to foster innovation within the diagnostics field. Their target market includes healthcare providers and researchers seeking cutting-edge diagnostic tools.
How much funding has Celula raised?
Celula has raised a total of $10M across 1 funding round:
Debt
$10M
Debt (2015): $10M with participation from Oxford Finance
Key Investors in Celula
Oxford Finance
Oxford Finance, founded in 2002, is a specialty finance firm that offers flexible financial solutions to healthcare and life sciences companies worldwide, indicating a focus on companies within Celula's sector.
What's next for Celula?
With a substantial enterprise-level funding context, Celula appears to be in a growth or scaling phase, likely post-Series A. The recent strategic investment suggests a focus on expanding market reach, further developing its technological pipeline, or potentially pursuing strategic acquisitions. Continued investment in R&D will be crucial for maintaining its competitive edge in the rapidly evolving diagnostics market. The company's commitment to enhancing women's health diagnostics positions it for significant future impact.
See full Celula company page
